Longitudinal metabolomics profiling of serum amino acids in rotenone-induced Parkinson's mouse model

Yan, Zhenzhen; Yang, Fan; Wen, Shirong; Ding, Wencai; Si, Yao; Li, Ruihua; Wang, Kai; Yao, Lifen

doi:10.1007/s00726-021-03117-1

Cited by 5 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the existing literature on the association between BCAAs and dementia, AD, and PD mostly consists of conventional studies lacking sufficient population-based prospective studies. For example, a longitudinal study showed the concentrations of leucine and isoleucine progressively decreased with the progression of PD ( Yan et al, 2022 ). Another study suggested that elevated plasma isoleucine levels were found to be associated with Alzheimer’s disease ( Larsson and Markus, 2017 ).…”

Section: Introductionmentioning

confidence: 99%

Branched-chain amino acids and the risks of dementia, Alzheimer’s disease, and Parkinson’s disease

Fu,

Wang,

Ren

et al. 2024

Front. Aging Neurosci.

View full text Add to dashboard Cite

BackgroundWe aimed to examine the association between blood levels of Branched-chain amino acids (BCAAs) - specifically isoleucine, leucine, and valine - and the susceptibility to three neurodegenerative disorders: dementia, Alzheimer’s disease (AD), and Parkinson’s disease (PD).MethodsBased on data from the UK Biobank, a Cox proportional hazard regression model and a dose–response relationship were used to analyze the association between BCAAs and the risks of dementia, AD, and PD. We also generated a healthy lifestyle score and a polygenic risk score. Besides, we conducted a sensitivity analysis to ensure the robustness of our findings.ResultsAfter adjusting for multiple covariates, blood concentrations of isoleucine, leucine, and valine were significantly associated with a reduced risk of dementia and AD. This association remained robust even in sensitivity analyses. Similarly, higher levels of isoleucine and leucine in the blood were found to be associated with an increased risk of PD, but this positive correlation could potentially be explained by the presence of covariates. Further analysis using a dose–response approach revealed that a blood leucine concentration of 2.14 mmol/L was associated with the lowest risk of dementia.ConclusionBCAAs have the potential to serve as a biomarker for dementia and AD. However, the specific mechanism through which BCAAs are linked to the development of dementia, AD, and PD remains unclear and necessitates additional investigation.

show abstract

Section: Introductionmentioning

confidence: 99%